Related Experiment Video

Updated: May 11, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

A Visual Analysis of the Research Dynamics in Resistance to EGFR Inhibitors for NSCLC

Jun Shao1, Yunru Gu1, Renhua Guo1

  • 1Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.

Drug Design, Development and Therapy
|July 1, 2024
PubMed
Abstract

Insights

Research on resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) is rapidly growing. This bibliometric analysis maps global research trends and key contributors in EGFR-TKI resistance.

Area of Science:

  • Oncology
  • Biomarkers
  • Pharmacology

Background:

  • Activating mutations in epidermal growth factor receptor (EGFR) are predictive biomarkers for EGFR tyrosine kinase inhibitor (TKI) treatment in non-small cell lung cancer (NSCLC).
  • Therapeutic resistance to EGFR-TKIs poses a significant challenge, necessitating a deeper understanding of resistance mechanisms and post-resistance strategies.
  • EGFR-mutant NSCLC research is critical for advancing novel treatment approaches.

Purpose of the Study:

  • To conduct a bibliometric analysis of research trends in resistance to EGFR-TKIs in NSCLC.
  • To identify key research areas, influential authors, institutions, and journals in the field of EGFR-TKI resistance.
  • To provide guidance for future research directions in overcoming EGFR-TKI resistance.

Main Methods:

  • Bibliometric analysis of 5866 documents on EGFR-TKI resistance in NSCLC, collected from the Web of Science Core Collection (WoSCC).
  • Utilized bibliometric tools including CiteSpace and VOSviewer for comprehensive analysis and visualization.
  • Examined publication output, citation counts, geographical distribution, institutional contributions, and author impact.

Main Results:

  • A significant increase in publications since 2016 indicates growing research interest.
  • China leads in publication volume, while the United States leads in citation impact.
  • Key research themes include genetic testing, resistance mechanisms, and post-resistance treatment strategies.

Conclusions:

  • The study provides a comprehensive overview of the research landscape concerning EGFR-TKI resistance in NSCLC.
  • Identifies influential contributors and emerging trends to guide future research efforts.
  • Highlights the need for continued investigation into understanding and overcoming resistance mechanisms for improved patient outcomes.
Keywords:
EGFR mutationEGFR-TKIsNSCLCbibliometric analysishot SPOTS

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...